Longjin pharmaceutical co.002750
80.660
SCIENCE & TECHNOLOGY
Scientific Research Leading Edge

Erigeron breviscapus, the local characteristic medicinal plant of Yunnan, was recorded in Herbs in the South of Yunnan (earlier than Compendium of Materia Medica by more than 150 years) at the earliest. Scutellarin is the main medicinal composition of erigeron breviscapus, and Longjin® breviscapine injection is the monomer purified preparation of scutellarin. As the erigeron breviscapus is continuously promoted and applied in the clinical field in recent years, the research on scutellarin—the main medicinal composition is carried out more profoundly. Some foreign research institutions have carried out relevant researches. Some of the published research achievements are briefly listed below:

image.png

The research of Yang Luling Medical School, National University of Singapore shows: The scutellarin is highly sensitive to the drug-evoked colon cancer cell through the enhanced tyrosine kinase (caspase-6) activation. (Chan JY, Tan BK, Lee SC. Scutellarin sensitizes drug-evoked colon cancer cell apoptosis through enhanced caspase-6 activation. Anticancer Res. 2009 Aug;29(8):3043-7.)

image.png

(Wang CZ, Li XL, Wang QF, Mehendale SR, Yuan CS.Selective fraction of Scutellaria baicalensis and its chemopreventive effects on MCF-7 human breast cancer cells. Phytomedicine. 2010 Jan;17(1):63-8.)

The University of Chicago conducted the comparative research for the effect of baicalein, wogonin, baicalin and scutellarin on human breast cancer cell. (Wang CZ, Li XL, Wang QF, Mehendale SR, Yuan CS.Selective fraction of Scutellaria baicalensis and its chemopreventive effects on MCF-7 human breast cancer cells. Phytomedicine. 2010 Jan;17(1):63-8.)

image.png

Bofferding A, Wingard CJ. Nitric oxide and catalase-sensitive relaxation by scutellarin in the mouse thoracic aorta. J Cardiovasc Pharmacol. 2009 Jan;53(1):66-76)

The research of Brody Medical School, East Carolina University verifies that: Longjin® breviscapine injection provided by Kunming Longjin Pharmaceutical Co., Ltd. repairs and protects the vascular endothelial cell. (Yang W, Lust RM, Bofferding A, Wingard CJ. Nitric oxide and catalase-sensitive relaxation by scutellarin in the mouse thoracic aorta. J Cardiovasc Pharmacol. 2009 Jan;53(1):66-76)


As the research is continuously deepened and developed, more research achievements will be applied clinically. Closely following the development pace, Longjin Pharmaceutical keeps the close cooperation and contact with foreign scientific research institutions, and is devoted to providing better and more innovative products to patients and creating more benefits for more patients.